Drug Type Antibody fusion proteins |
Synonyms JR-479 |
Target |
Mechanism HEXA modulators(hexosaminidase subunit alpha modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gangliosidoses, GM2 | Preclinical | JP | 15 Jul 2024 | |
Lysosomal Storage Diseases | Preclinical | - | 18 Mar 2022 |